Health care and life science organizations have always prioritized saving lives and now extend that commitment to environmental, social and governance (ESG) goals. They are not merely checking boxes, but genuinely pursuing long term impact for individuals, future generations and the planet. However, they must now elevate their ESG efforts to
The COVID-19 pandemic brought an enormous urgency to the life sciences sector. Companies vied for suitable treatments and in less than a year, COVID-19 vaccines were developed. This demonstrated clearly that the sector could move at speed when necessary. Though vaccines were supported by regulators, inefficiencies in vaccine and drug development were exposed.